Regulatory milestones

Amgen Inc. (NASDAQ:AMGN) gained $0.67 to $82.03 last week after FDA approved an sBLA for Prolia denosumab to increase bone mass in men with osteoporosis at high risk for fracture. Prolia is already approved in the U.S. and EU to treat osteoporosis in postmenopausal women and in the EU to treat bone loss associated with hormone ablation in men with prostate cancer. The product is approved in the U.S. and EU as Xgeva to prevent skeletal related events in adults with bone metastases from solid tumors.